BALAMINES - Balaji Amines Ltd. Share Price

Management provided a positive outlook for Balaji Amines Limited, noting stable demand and ongoing strategic projects. They anticipate a revenue growth target reaching INR 3,000 crores by FY28, buoyed by expansion in specialty chemicals and new product lines.

For Q4 FY26, consolidated total revenue reached INR 403 crores, indicating a year-on-year growth of 12% from INR 361 crores in Q4 FY25. Consolidated EBITDA improved to INR 102 crores with an EBITDA margin of 25%, up from 19% in Q4 FY25, reflecting better operating leverage and efficient cost management. Profit after tax saw notable growth, standing at INR 65 crores compared to INR 40 crores in Q4 FY25.

Management plans to maintain upward momentum, predicting a volume growth of 25% to 30% in FY27, supported by new projects such as Dimethyl Ether (DME) and N-Methyl Morpholine (NMM). The DME plant is expected to commence operations in Q1 FY27, with a capacity of 100,000 tons, aiming for 30% to 40% utilization in FY27. The forecast is contingent upon obtaining road transport permissions for DME.

They are also focusing on ramping up production of advanced specialty chemicals including Hydrogen Cyanide and Sodium Cyanide, anticipating strong demand for these products domestically and internationally. Management emphasizes ongoing monitoring of raw material prices and geopolitical developments, assuring stakeholders that Balaji Amines is well-positioned for gradual growth, underpinned by a diversified product portfolio and robust relationships with customers.

1. Question: "Looking at your expansion plan, given the current utilization levels, why would you continue further expansions despite remaining at such a low utilization?"

   • Answer: "New projects, like Dimethyl Ether and improved Acetonitrile, focus on different products, not just expanding existing capacities. Our current low utilization is temporary, and we're preparing for future demands. Products like DMF and butylamines have seen low utilization due to the slow uptake from battery manufacturers, but we're readying for tomorrow's requirements."

2. Question: "What is the average price hike you took in the current quarter due to global supply chain disruptions?"

   • Answer: "Prices have escalated due to geopolitical issues, with some materials up 2.5 times. We've effectively managed inventory and received customer uptake to maintain profits. We anticipate 25-30% volume growth this year, with sustainable EBITDA margins between 22-23%."

3. Question: "Could you quantify the risks from a large metformin customer that backward integrated?"

   • Answer: "The backward integration might seem significant, but this customer only accounts for 15-20% of our Di-Methyl Amine Hydrochloride sales. They still source from us due to potentially better cost production on our side."

4. Question: "What's the update on DME's approval from the government?"

   • Answer: "We have the manufacturing permissions; only transportation approvals are pending. With India heavily dependent on LPG imports, our planned 100,000 MT DME will help meet demand, especially as LPG costs rise."

5. Question: "What will be the expected capex remaining for DME, NMM, and ACN this year?"

   • Answer: "A balance of about INR20 crores remains for these plants. We have advanced payments for equipment, and significant spending has already occurred."

6. Question: "What does your guidance of achieving INR 3,000 crores in revenue by FY28 depend on?"

   • Answer: "Our growth will primarily come from ramping up Balaji Specialty Chemicals and the DME project, along with strong domestic demand for our specialized chemicals."

7. Question: "What are the expected margins for the DME plant once operational?"

   • Answer: "Utilization may initially reach 30-40% in the first year, growing to 80-90% thereafter. Margins are estimated similar to current chemical margins around 22-23%."

8. Question: "On the battery chemicals unit, how much have you invested, and is it operational?"

   • Answer: "The unit is operational at 20-25% capacity, although not yet fully utilized for battery chemicals. Initial orders are coming in, primarily fulfilling external demands."

9. Question: "Will we see commercial production of DME from Q1?"

   • Answer: "Yes, we anticipate starting DME supplies from Q1, pending road transportation permissions. We're actively testing with customers to ensure quality prior to bulk orders."

10. Question: "What is your outlook for FY27 in terms of volume and sales?"

    • Answer: "We're expecting a conservative volume growth of 10-15% for the year, with ongoing projects like DME and ACN contributing progressively as they stabilize."